Drogas e Sistema Nervoso Periférico I
Neuropatias Tóxicas Induzidas por Drogas
DOI:
https://doi.org/10.34024/rnc.1999.v7.10313Palavras-chave:
Neuropatia periférica, toxicidade, drogasResumo
Continuamente aumenta nosso conhecimento sobre os mecanismos patofisiológicos das várias doenças e aumenta o número das drogas que podem ser usadas para tratá-las. Entretanto, muitas das drogas para o tratamento de doenças clínicas, incluindo as neurológicas, podem causar toxicidade sistêmica e disfunção neurológica. Os autores apresentam uma revisão da toxicidade sobre o sistema nervoso periférico induzida pelas diversas drogas em uso corrente.
Métricas
Carregando Métricas ...
Referências
1. Le Witt PA, Forno LS. Peripheral neuropathy following amitriptyline overdose. Muscle Nerve, 8:723-724, 1985.
2. Ramilo O, Kinane BT, McCraken GH. Chloramphenicol neurotoxicity. Pediatr Infect J, 7:358-359, 1988.
3. Whisnatt JP, Estes ML, Kierland RR, Lambert EH. Chloroquine neuromyopathy. Proc Mayo Clin, 38:501-509, 1963.
4. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M et al. Cloroquine neuromyotoxicity – clinical and pathologic perspective. Am J Med, 82:447-455, 1987.
5. Tegner R, Tomé FMS, Godou P. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol, 75:253-268, 1988.
6. Kuncl RW, Duncan G, Watson D, Alderson K, Rogowski MA et al. Colchicine myopathy and neuropathy. N Engl J Med, 316:1562-1568, 1981.
7. Riggs JE, Schochet SS, Gutmann L. Chronic human colchicine neuropathy and myopathy. Arc Neurol, 43:521-527. 1986.
8. Ansbacher LE, Bosch EP, Concilla PA. Dissulfiram neuropathy – a neurofilamentous distal axonopathy. Neurology, 32:424-428, 1982.
9. Nukada H, Pollock M. Dissulfiram neuropathy – a morphometric study of sural nerve. J Neurol Sci, 51-60, 1981.
10. Nair US, Le Brun M, Kass I. Peripheral neuropathy associated with ethambutol. Chest, 77:98-100, 1980.
11. Swift TR, Gross JA, Ward C, Crout BO. Peripheral neuropathy in epileptic patients. Neurology, 31:826-831, 1981.
12. Ramirez JA, Mendell JR, Warnolts R, Griggs RC. Phenytoin neuropathy – structural changes in the sural nerve. Ann Nerol, 19:162-167, 1986.
13. Raskin DM, Fischman PA. Pyrydoxine – deficiency neuropathy due to hydralazine. N Engl J Med, 273:1182-1187, 1965.
14. Ochoa J. Isoniazid neuropathy in man – quantitative electronmicroscope study. Brain, 93:831-846, 1970.
15. Jacobs JM, Miller RH, Whittle A, Cavanagh JB. Studies on the early changes of acute isoniazid neuropathy in the rat. Act Neuropathol, 47:85-96, 1979.
16. Schlaepfer WW, Hager H. Ultrastructural studies of INHinduced neuropathy in rats. Am J Pathol, 45:423-434, 1964.
17. Pamphlett RS, Mackenzie RA. Severe peripheral neuropathy due to lithium intoxication. J Neurol Neurosurg Psychiatry, 45:656-661, 1982.
18. Bradley WG, Bennett RK, Good P. Metronidazole neuropathy. Br Med J, 2:610-611, 1977.
19. Coxon A, Pallis CA. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry, 39:403-505, 1976.
20. Lhermitte R, Fardeau M, Chedru F. Polynevrites au cours de traitements par la nitrofurantoine. Presse Med. 71:767-774, 1963.
21. Yannikas C, Pollard JD, MacLeod JG. Nitrofurantoin neuropathy. Arch Phys Med Rehabil, 11:400-405, 1981.
22. Browne MJ, Mayer KH, Chaffre SBB, Dudley MN, Posner MR et al. 2’3’didehydro-2’3’dideoxytimidine – d4T – in patients with AIDS or AIDS-related complex – a phase I trial. J Infect Dis, 167:21-29, 1993.
23. Whittington R, Brogdan RN. Zalcitabine – A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs, 4:656-683, 1992.
24. Liebman HÁ, Cooley TP. Didanosine in treatment of AIDS or AIDS-related complex – a critical apraisal of the dose and frequency of administration. Clin Infect Dis, 16:550-558, 1993.
25. Schaumberg HH. ddC neuropathy – a study of 52 patients. Neurology, 40(suppl):428, 1990.
26. Dubinski RM. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2’3’dideoxycytidine (ddC). Muscle Nerve, 12:856-860, 1989.
27. Katrak SM, Pollock M, O’Brien CP. Clinical and morphological features of gold neuropathy. Brain, 103:671-693, 1980.
28. Walsh JC. Gold neuropathy. Neurology, 20:455-458, 1970.
29. Masurowsky EB, Peterson ER, Crain SM. Morphologic alterations in dorsal root ganglia neurons and supporting cell of organotypic mouse spinal cord ganglion cultures exposed to Taxol. J Natl Cancer Inst, 86:18-24, 1994.
30. Guihenec P, Ginet J, Grouleau JY, Rojouan J. Early phase of vincristine neuropathy in man. J Neurol Sci, 45:355-366, 1980.
31. Casey EB, Jellefe AM, LeQuesne PM, Millett YL. Vincristine neuropathy – clinical and electrophysiological observations. Brain, 96:69-86, 1973.
32. McLeod JG, Penny R. Vincristine neuropathy – An electrophysiologic and hystological study. J Neurol Neurosur Psychiatry, 32:297-312, 1969.
33. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve, 10:80-89, 1987.
34. Ahrens EM, Meckler RJ, Callen JP. Dapsone-induced peripheral neuropathy. Int J Dermatol, 25:314-316, 1986.
35. Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy – an axonal disease. Neurology, 26:514-516, 1976.
36. Roelfs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatinum chemotherapy. Neurology, 34:934-938, 1984.
37. Riggs JE, Asharf M, Snyder RD, Gutmann L. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol, 23:92-94, 1984.
38. Thompson SW, Davis LE, Kornfeldt M. Cisplatin neuropathy – clinical, electrophysiological, morphologic and toxicologic studies. Cancer, 54:1269- 127, 1984.
39. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology, 35:1466-1468, 1985.
40. Schaumberg H, Kaplan J, Windebrand A, Vick N, Reimuss S et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med, 309:445-458, 1983.
41. Langueny A, Rommel A, Vignolli B, Taub A. Thalidomide neuropathy – an electrophysiologic study. Muscle Nerve, 9:837-844, 1986.
42. Jacobs JM, Costa-Jussá FR. The pathology of amiodarone neurotoxicity I – Experimental studies with reference to changes in other tissues. Brain, 108:735-752, 1985.
43. Jacobs JM, Costa-Jussá FR. The pathology of amiodarone neurotoxicity II – Peripheral neuropathy in man. Brain, 108:753-769, 1985.
44. Fraser AG, McQueen INF, Watt AH. Peripheral neuropathy in long term high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry, 48:576-578,1985.
45. Borgeat A, deMuralt B, Stadler M. Peripheral neuropathy with high-dose ara-C therapy. Cancer, 58:852-854, 1986.
2. Ramilo O, Kinane BT, McCraken GH. Chloramphenicol neurotoxicity. Pediatr Infect J, 7:358-359, 1988.
3. Whisnatt JP, Estes ML, Kierland RR, Lambert EH. Chloroquine neuromyopathy. Proc Mayo Clin, 38:501-509, 1963.
4. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M et al. Cloroquine neuromyotoxicity – clinical and pathologic perspective. Am J Med, 82:447-455, 1987.
5. Tegner R, Tomé FMS, Godou P. Morphological study of peripheral nerve changes induced by chloroquine treatment. Acta Neuropathol, 75:253-268, 1988.
6. Kuncl RW, Duncan G, Watson D, Alderson K, Rogowski MA et al. Colchicine myopathy and neuropathy. N Engl J Med, 316:1562-1568, 1981.
7. Riggs JE, Schochet SS, Gutmann L. Chronic human colchicine neuropathy and myopathy. Arc Neurol, 43:521-527. 1986.
8. Ansbacher LE, Bosch EP, Concilla PA. Dissulfiram neuropathy – a neurofilamentous distal axonopathy. Neurology, 32:424-428, 1982.
9. Nukada H, Pollock M. Dissulfiram neuropathy – a morphometric study of sural nerve. J Neurol Sci, 51-60, 1981.
10. Nair US, Le Brun M, Kass I. Peripheral neuropathy associated with ethambutol. Chest, 77:98-100, 1980.
11. Swift TR, Gross JA, Ward C, Crout BO. Peripheral neuropathy in epileptic patients. Neurology, 31:826-831, 1981.
12. Ramirez JA, Mendell JR, Warnolts R, Griggs RC. Phenytoin neuropathy – structural changes in the sural nerve. Ann Nerol, 19:162-167, 1986.
13. Raskin DM, Fischman PA. Pyrydoxine – deficiency neuropathy due to hydralazine. N Engl J Med, 273:1182-1187, 1965.
14. Ochoa J. Isoniazid neuropathy in man – quantitative electronmicroscope study. Brain, 93:831-846, 1970.
15. Jacobs JM, Miller RH, Whittle A, Cavanagh JB. Studies on the early changes of acute isoniazid neuropathy in the rat. Act Neuropathol, 47:85-96, 1979.
16. Schlaepfer WW, Hager H. Ultrastructural studies of INHinduced neuropathy in rats. Am J Pathol, 45:423-434, 1964.
17. Pamphlett RS, Mackenzie RA. Severe peripheral neuropathy due to lithium intoxication. J Neurol Neurosurg Psychiatry, 45:656-661, 1982.
18. Bradley WG, Bennett RK, Good P. Metronidazole neuropathy. Br Med J, 2:610-611, 1977.
19. Coxon A, Pallis CA. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry, 39:403-505, 1976.
20. Lhermitte R, Fardeau M, Chedru F. Polynevrites au cours de traitements par la nitrofurantoine. Presse Med. 71:767-774, 1963.
21. Yannikas C, Pollard JD, MacLeod JG. Nitrofurantoin neuropathy. Arch Phys Med Rehabil, 11:400-405, 1981.
22. Browne MJ, Mayer KH, Chaffre SBB, Dudley MN, Posner MR et al. 2’3’didehydro-2’3’dideoxytimidine – d4T – in patients with AIDS or AIDS-related complex – a phase I trial. J Infect Dis, 167:21-29, 1993.
23. Whittington R, Brogdan RN. Zalcitabine – A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs, 4:656-683, 1992.
24. Liebman HÁ, Cooley TP. Didanosine in treatment of AIDS or AIDS-related complex – a critical apraisal of the dose and frequency of administration. Clin Infect Dis, 16:550-558, 1993.
25. Schaumberg HH. ddC neuropathy – a study of 52 patients. Neurology, 40(suppl):428, 1990.
26. Dubinski RM. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2’3’dideoxycytidine (ddC). Muscle Nerve, 12:856-860, 1989.
27. Katrak SM, Pollock M, O’Brien CP. Clinical and morphological features of gold neuropathy. Brain, 103:671-693, 1980.
28. Walsh JC. Gold neuropathy. Neurology, 20:455-458, 1970.
29. Masurowsky EB, Peterson ER, Crain SM. Morphologic alterations in dorsal root ganglia neurons and supporting cell of organotypic mouse spinal cord ganglion cultures exposed to Taxol. J Natl Cancer Inst, 86:18-24, 1994.
30. Guihenec P, Ginet J, Grouleau JY, Rojouan J. Early phase of vincristine neuropathy in man. J Neurol Sci, 45:355-366, 1980.
31. Casey EB, Jellefe AM, LeQuesne PM, Millett YL. Vincristine neuropathy – clinical and electrophysiological observations. Brain, 96:69-86, 1973.
32. McLeod JG, Penny R. Vincristine neuropathy – An electrophysiologic and hystological study. J Neurol Neurosur Psychiatry, 32:297-312, 1969.
33. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve, 10:80-89, 1987.
34. Ahrens EM, Meckler RJ, Callen JP. Dapsone-induced peripheral neuropathy. Int J Dermatol, 25:314-316, 1986.
35. Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy – an axonal disease. Neurology, 26:514-516, 1976.
36. Roelfs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatinum chemotherapy. Neurology, 34:934-938, 1984.
37. Riggs JE, Asharf M, Snyder RD, Gutmann L. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol, 23:92-94, 1984.
38. Thompson SW, Davis LE, Kornfeldt M. Cisplatin neuropathy – clinical, electrophysiological, morphologic and toxicologic studies. Cancer, 54:1269- 127, 1984.
39. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology, 35:1466-1468, 1985.
40. Schaumberg H, Kaplan J, Windebrand A, Vick N, Reimuss S et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med, 309:445-458, 1983.
41. Langueny A, Rommel A, Vignolli B, Taub A. Thalidomide neuropathy – an electrophysiologic study. Muscle Nerve, 9:837-844, 1986.
42. Jacobs JM, Costa-Jussá FR. The pathology of amiodarone neurotoxicity I – Experimental studies with reference to changes in other tissues. Brain, 108:735-752, 1985.
43. Jacobs JM, Costa-Jussá FR. The pathology of amiodarone neurotoxicity II – Peripheral neuropathy in man. Brain, 108:753-769, 1985.
44. Fraser AG, McQueen INF, Watt AH. Peripheral neuropathy in long term high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry, 48:576-578,1985.
45. Borgeat A, deMuralt B, Stadler M. Peripheral neuropathy with high-dose ara-C therapy. Cancer, 58:852-854, 1986.
Downloads
Publicado
1999-09-30
Edição
Seção
Artigos Originais
Como Citar
Drogas e Sistema Nervoso Periférico I: Neuropatias Tóxicas Induzidas por Drogas . (1999). Revista Neurociências, 7(3), 108-114. https://doi.org/10.34024/rnc.1999.v7.10313
